- AU$10.20m
- AU$13.58m
- AU$4.86m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 469.9 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -177.6% | ||
| Return on Equity | -412.13% | ||
| Operating Margin | -36.58% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 4.06 | 4.62 | 5.26 | 4.5 | 4.86 | n/a | n/a | 3.86% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CardieX Limited is an Australia-based health technology company. It is engaged in designing, manufacturing, and marketing medical devices for use in cardiovascular health management, and the development of clinical and consumer digital health solutions. It is focused on hypertension, cardiovascular disease, and other vascular health disorders. It operates through its subsidiaries, including ATCOR and CONNEQT. ATCOR division provides medical devices for measuring arterial stiffness and central blood pressure waveforms based on its SphygmoCor technology. Under the ATCOR.X brand, it also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. Its digital platform, ArtyNet, is a connected software as a service ecosystem providing physicians with a telehealth solution for remotely managing patients’ health. CONNEQT develops and markets consumer wearable and home health devices focused on heart health and its patented fitness parameters.
Directors
- Niall Cairns CHM
- Craig Cooper CEO
- Jarrod White CFO
- Chris Dax CEX
- Rhonda Welch VPR
- Douglas Kurschinski GMG
- Mark Harding OTH
- Nicholas Marshall SEC
- Randall Nelson NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 7th, 2005
- Public Since
- November 9th, 2005
- No. of Shareholders
- 2,381
- No. of Employees
- 26
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 143,683,524
- Address
- Suite 301, 15 Lime St., SYDNEY, NSW 2000
- Web
- https://cardiex.com/
- Phone
- +61 298748761
- Auditors
- BDO Audit Pty Ltd
Upcoming Events for CDX
Similar to CDX
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Allegra Medical Technologies
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
FAQ
What is the Cardiex share price?
As of Today at 19:04 UTC, shares in Cardiex are trading at AU$0.07. This share price information is delayed by 15 minutes.
How has the Cardiex share price performed this year?
Shares in Cardiex last closed at AU$0.07 and the price had moved by -77.1% over the past 365 days. In terms of relative price strength the Cardiex share price has underperformed the ASX All Ordinaries Index by -78.09% over the past year.
What are the analyst and broker recommendations for Cardiex?
There is no consensus recommendation for this security.
What is the Cardiex dividend yield?
Cardiex does not currently pay a dividend.
Does Cardiex pay a dividend?
Cardiex does not currently pay a dividend.
When does Cardiex next pay dividends?
Cardiex does not currently pay a dividend.
How do I buy Cardiex shares?
To buy shares in Cardiex you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cardiex?
As of the previous close price of AU$0.07, shares in Cardiex had a market capitalisation of AU$10.20m.
Where are Cardiex shares listed?
Here are the trading details for Cardiex:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CDX
What kind of share is Cardiex?
Based on an overall assessment of its quality, value and momentum Cardiex is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cardiex share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Cardiex share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cardiex. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -47.68%.
As of the last closing price of AU$0.07, shares in Cardiex were trading -63.53% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cardiex PE Ratio?
The Cardiex PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cardiex?
Cardiex's management team is headed by:
- Niall Cairns - CHM
- Craig Cooper - CEO
- Jarrod White - CFO
- Chris Dax - CEX
- Rhonda Welch - VPR
- Douglas Kurschinski - GMG
- Mark Harding - OTH
- Nicholas Marshall - SEC
- Randall Nelson - NID